Trevena to Present at the JMP Securities Life Sciences Conference

Rhea-AI Summary

Trevena, Inc. (TRVN), a biopharmaceutical company, announced that CEO Carrie Bourdow will participate in a fireside chat at the JMP Securities Life Sciences Conference, scheduled for June 16-17, 2021. Bourdow's presentation is set for 1:30 PM ET on June 16. The event aims to highlight Trevena’s work on novel CNS therapies, including their approved product OLINVYK (oliceridine) and investigational candidates for treating conditions like migraine and opioid use disorder. Webcast details are available through Trevena's investor portal.

CHESTERBROOK, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. will participate in a fireside chat at the JMP Securities Life Sciences Conference being held virtually June 16 - 17, 2021.

Presentation Details
Date:	Wednesday, June 16, 2021
Time:	1:30 pm Eastern Time
Presenter:	Carrie Bourdow, President & CEO
Webcast:	https://wsw.com/webcast/jmp49/trvn/1718600

A link to the webcast will be available on the Events page of the Investors section of the Company’s website at https://www.trevena.com/investors/events-presentations/ir-calendar. A replay of the presentation will be archived on the website and available for approximately 30 days following the event. Please contact your JMP Securities representative to schedule virtual one-on-one meetings with Trevena during the conference.

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK^® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s novel pipeline is based on Nobel Prize winning research and includes four differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for diabetic neuropathic pain and epilepsy, and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients.

For more information, please visit www.Trevena.com.

Investor Contact:

Daniel Ferry
LifeSci Advisors
Phone: 617-430-7576
Email: IR@trevena.com

Company Contact:

Sasha Bennett
Director
Clyde Group
Sasha.Bennett@clydegroup.com
(239) 248-3409

FAQ

What is the date and time of Trevena's presentation at the JMP Securities Life Sciences Conference?

Trevena's presentation is scheduled for June 16, 2021, at 1:30 PM Eastern Time.

Who will represent Trevena, Inc. at the JMP Securities Life Sciences Conference?

Carrie Bourdow, President and CEO of Trevena, will represent the company.

Where can I watch the Trevena presentation from the JMP Securities Life Sciences Conference?

The presentation can be watched via webcast at https://wsw.com/webcast/jmp49/trvn/1718600.

What products and candidates does Trevena have?

Trevena has one approved product, OLINVYK (oliceridine), and several investigational candidates including TRV250, TRV734, TRV045, and TRV027.

What is Trevena, Inc.'s focus area in biopharmaceuticals?

Trevena focuses on developing and commercializing innovative medicines for central nervous system disorders.